mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether.

The antimalarial artemisinin derivatives artesunate (ART), arteether (ARE), and artemether (ARM) reveal remarkable antineoplastic activity. In the present investigation, we identified mRNA expression profiles associated with the response of tumor cells to ART, ARE, and ARM. We performed correlation and hierarchical cluster analyses of inhibition concentration 50% (IC(50)) values and basal mRNA expression levels of 464 genes deposited in the database of the National Cancer Institute, USA. Correlating IC(50) values of ART, ARE, and ARM and of 16 established antineoplastic drugs revealed that the artemisinin derivatives could not be assigned with a known class of drugs with defined mode(s) of action. The basal mRNA expression of 208 out of 464 genes (45%) correlated significantly with IC(50) values of at least one artemisinin derivative. These genes were from different classes (drug resistance genes, DNA damage and repair genes, apoptosis-regulating genes, proliferation-associated genes, oncogenes, tumor suppressor genes and cytokines). We identified two different gene clusters by hierarchical cluster analysis. One cluster contained predominately genes significantly correlated to all three artemisinin derivatives. This overlapping set of genes points to common molecular mechanisms of tumor inhibition by all three drugs in which genes affecting cellular proliferation may play an important role. The second cluster contained genes differentially associated with the response of artemisinin derivatives to cancer cells. The number of correlating drug resistance genes in this cluster increased in the order ART<ARE<ARM and was paralleled by increasing IC(50) values of the three drugs in the same order. The higher activity of ART in comparison to ARE and ARM may, thus, be explained by a lower number of drug resistance genes affecting ARTs action. The present analysis is a starting point for the generation of hypotheses on candidate genes and for a more detailed dissection of the functional role of individual genes for the activity of artemisinin derivatives in tumor cells.

[1]  S. Meshnick,et al.  Reaction of antimalarial endoperoxides with specific parasite proteins , 1994, Antimicrobial Agents and Chemotherapy.

[2]  G. Brittinger,et al.  In Acute Myeloid Leukemia only the Coexpression of at Least Two Proteins Including P-Glycoprotein, the Multidrug Resistance-Related Protein MRP, bcl-2, Mutant p53 and Heat-Shock Protein 27 is Predictive for the Response to Induction Chemotherapy , 1998 .

[3]  D A Scudiero,et al.  Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. , 1989, Journal of the National Cancer Institute.

[4]  F. Gay,et al.  In-vitro tests on Philippine isolates of Plasmodium falciparum against four standard antimalarials and four qinghaosu derivatives. , 1994, Bulletin of the World Health Organization.

[5]  Y. Tu,et al.  The development of new antimalarial drugs: qinghaosu and dihydro-qinghaosu. , 1999, Chinese medical journal.

[6]  H. J. Woerdenbag,et al.  Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells. , 1993, Journal of natural products.

[7]  M. Overman,et al.  Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity. , 2000, International journal of oncology.

[8]  T. Efferth,et al.  Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. , 2002, Blood cells, molecules & diseases.

[9]  J. G. Cory,et al.  Multifactorial mechanisms of drug resistance in tumor cell populations selected for resistance to specific chemotherapeutic agents. , 1998, Advances in enzyme regulation.

[10]  T. Efferth,et al.  The anti-malarial artesunate is also active against cancer. , 2001, International journal of oncology.

[11]  D. L. Klayman,et al.  Qinghaosu (artemisinin): an antimalarial drug from China , 1985 .

[12]  M. Volm,et al.  Expression of several resistance mechanisms in untreated human kidney and lung carcinomas. , 1992, Anticancer research.

[13]  Y. Pommier,et al.  Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen. , 1994, Journal of the National Cancer Institute.

[14]  T Tanaka,et al.  Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. , 2001, Cancer research.

[15]  G. Goldenberg,et al.  Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia. , 1988, Cancer research.

[16]  D A Scudiero,et al.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. , 1988, Cancer research.

[17]  P. Berman,et al.  Artemisinin enhances heme-catalysed oxidation of lipid membranes. , 1997, Free radical biology & medicine.

[18]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.